Dianthus Therapeutics (DNTH) to Release Earnings on Thursday

Key Points

• Dianthus Therapeutics (NASDAQ: DNTH) is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.86) per share.
• The company's recent Q1 earnings report showed a loss of ($0.82) per share, exceeding expectations with revenue of $1.16 million against an estimate of $0.81 million.
• Stock for Dianthus Therapeutics is currently down 4.0%, with a recent market cap of $655.74 million and a consensus target price of $53.00 from analysts.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.86) per share and revenue of $0.87 million for the quarter.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. On average, analysts expect Dianthus Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dianthus Therapeutics Stock Down 2.0%

Shares of NASDAQ:DNTH traded down $0.39 during midday trading on Friday, hitting $18.76. 307,019 shares of the stock traded hands, compared to its average volume of 320,251. The business's 50 day moving average is $19.26 and its two-hundred day moving average is $20.08. The stock has a market capitalization of $603.32 million, a PE ratio of -6.51 and a beta of 1.43. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $32.27.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DNTH. William Blair initiated coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an "outperform" rating for the company. Robert W. Baird decreased their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $53.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Dianthus Therapeutics stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 4.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,334 shares of the company's stock after buying an additional 618 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Dianthus Therapeutics were worth $280,000 as of its most recent SEC filing. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.